Supplementation with vitamin E but not with vitamin C lowers lipid peroxidation in vivo in mildly hypercholesterolemic men

References

• Rimm E.B., Stampfer M.J., Ascherio A., Giovannucci E., Colditz G.A., Willet W.C. Vitamin E consumption and the risk of coronary heart disease in men. New England Journal of Medicine 1993; 328: 1450–1456
   PubMed Web of Science ®Google Scholar
• Stampfer M.J., Hennekens C.H., Manson J.E., Coditz G.A., Rosner B., Willett W.C. Vitamin E consumption and risk of coronary disease in women. New England Journal of Medicine 1993; 328: 1444–1449
   PubMed Web of Science ®Google Scholar
• Enstrom J.E., Kanim L.E., Klein M.A. Vitamin C intake and mortality among a sample of the United States population. Epidemiology 1992; 3: 194–202
   PubMed Web of Science ®Google Scholar
• Salonen J.T. Epidemiological studies on LDL oxidation, pro- and antioxidants and atherosclerosis. Free Radicals, Lipoprotein Oxidation and Atherosclerosis: Biological and Clinical Aspects, G. Bellomo, G. Finardi, E. Maggi, C. Rice-Evans. Richlieu Press, London 1995; 27–52
   Google Scholar
• Salonen J.T., Nyyssönen K., Parviainen M.T. Vitamin C, lipid peroxidation, and the risk of myocardial infarction: epidemiological evidence from eastern Finland. Vitamin C in Health and Disease. Marcel Dekker, New York 1997; 457–469
   Google Scholar
• Nyyssönen K., Parviainen M.T., Salonen R., Tuomilehto J., Salonen J.T. Vitamin C deficiency and risk of myocardial infarction: prospective population study of men from eastern Finland. BMJ 1997; 314: 634–638
   PubMed Web of Science ®Google Scholar
• Stephens N.G., Parsons A., Schofield P.M., Kelly F., Cheeseman K., Mitchinson M.J. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347: 781–786
   PubMed Web of Science ®Google Scholar
• Collaborative group of the primary prevention project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 2001; 357: 89–95
   PubMed Web of Science ®Google Scholar
• The heart outcomes prevention evaluation study investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. New England Journal of Medicine 2000; 342: 154–160
   PubMed Web of Science ®Google Scholar
• Diaz M.N., Frei B., Vita J.A., Keaney J.F., Jr. Antioxidants and atherosclerotic heart disease. New England Journal of Medicine 1997; 337: 408–416
   PubMed Web of Science ®Google Scholar
• Frei B., England L., Ames B.N. Ascorbate is an outstanding antioxidant in human blood plasma. Proceedings of the National Academy of Sciences of USA 1989; 86: 6381–6377
   Google Scholar
• Frei B. Ascorbic acid protects lipids in human plasma and low-density lipoprotein against oxidative damage. American Journal of Clinical Nutrition 1991; 54: 1113S–1118S
   PubMed Web of Science ®Google Scholar
• Jialal I., Grundy S.M. Preservation of the endogenous antioxidants in low density lipoprotein by ascorbate but not probucol during oxidative modification. Journal of Clinical Investigation 1991; 87: 597–601
   PubMed Web of Science ®Google Scholar
• Retsky K.L., Freeman M.W., Frei B. Ascorbic acid oxidation product(s) protect human low density lipoprotein against atherogenic modification. Journal of Biological Chemistry 1993; 268: 1304–1309
   PubMed Web of Science ®Google Scholar
• Dieber-Rotheneder M., Puhl H., Waeg G., Striegl G., Esterbauer H. Effect of oral supplementation with D-alpha-tocopherol on the vitamin E content of human low density lipoproteins and resistance to oxidation. Journal of Lipid Research 1991; 32: 1325–1332
   PubMed Web of Science ®Google Scholar
• Jialal I., Grundy S.M. Effect of dietary supplementation with alpha-tocopherol on the oxidative modification of low density lipoprotein. Journal of Lipid Research 1992; 33: 899–906
   PubMed Web of Science ®Google Scholar
• Princen H.M.G., van Poppel G., Vogelezang C., Buytenhek R., Kok F.J. Supplementation with vitamin E but not β-carotene in vivo protects low density lipoprotein from lipid peroxidation in vitro. Effect of cigarette smoking. Arteriosclerosis and Thrombosis 1992; 12: 554–562
   PubMed Web of Science ®Google Scholar
• Reaven P.D., Witztum J.L. Comparison of supplementation of RRR-alpha-tocopherol and racemic alpha-tocopherol in humans. Effects on lipid levels and lipoprotein susceptibility to oxidation. Arteriosclerosis and Thrombosis 1993; 13: 601–608
   PubMed Web of Science ®Google Scholar
• Jialal I., Fuller C.J., Huet B.A. Effect of alpha-tocopherol supplementation on LDL oxidation: dose-response study. Arteriosclerosis, Thrombosis and Vascular Biology 1995; 15: 190–198
   PubMed Web of Science ®Google Scholar
• Princen H.M.G., van Duyvenvoorde W., Buytenhek R., van der Laarse A., vanPoppel G., Gevers J.A., van Hinsbergh V.W.M. Supplementation with low doses of vitamin E protects LDL from lipid peroxidation in men and women. Arteriosclerosis, Thrombosis, and Vascular Biology 1995; 15: 325–333
   PubMed Web of Science ®Google Scholar
• Fuller C.J., Grundy S.M., Norkus E.P., Jialal I. Effect of ascorbate supplementation on low density lipoprotein oxidation in smokers. Atherosclerosis 1996; 119: 139–150
   PubMed Web of Science ®Google Scholar
• Harats D., Ben-Naim M., Dabach Y., Hollander G., Havivi E., Stein O., Stein Y. Effect of vitamin C and E supplementation on susceptibility of plasma lipoproteins to peroxidation induced by acute smoking. Atherosclerosis 1990; 85: 47–54
   PubMed Web of Science ®Google Scholar
• Rifici V.A., Khachadurian A.K. Dietary Supplementation with vitamins C and E inhibits in vitro oxidation of lipoproteins. Journal of the American College of Nutrition 1993; 12: 631–637
   PubMed Web of Science ®Google Scholar
• Nyyssönen K., Poulsen H.E., Hayn M., Agerbo P., Porkkala-Sarataho E., Kaikkonen J., Salonen R., Salonen J.T. Effect of supplementation of smoking men with plain or slow release ascorbic acid on lipoprotein oxidation. European Journal of Clinical Nutrition 1997; 51: 154–163
   PubMedGoogle Scholar
• Hwang J., Peterson H., Hodis H.N., Choi B., Sevanian A. Ascorbic acid enhances 17 beta-estradiol-mediated inhibition of oxidized low density lipoprotein formation. Atherosclerosis 2000; 150: 275–284
   PubMed Web of Science ®Google Scholar
• Valkonen M.M., Kuusi T. Vitamin C prevents the acute atherogenic effects of passive smoking. Free Radical Biology and Medicine 2000; 28: 428–436
   PubMedGoogle Scholar
• Reilly M., Delanty N., Lawson J.A., FitzGerald G.A. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 1996; 94: 19–25
   PubMed Web of Science ®Google Scholar
• Panda K., Chattopadhyay R., Chattopadhyay D.J., Chatterjee I.B. Vitamin C prevents cigarette smoke-induced oxidative damage in vivo. Free Radical Biology and Medicine 2000; 29: 115–124
   PubMed Web of Science ®Google Scholar
• Porkkala-Sarataho E., Salonen J.T., Nyyssönen K., Kaikkonen J., Salonen R., Ristonmaa U., Diczfalusy U., Brigelius-Flohe R., Loft S., Poulsen H.E. Long-term effects of vitamin E, vitamin C, and combined supplementation on urinary 7-hydro-8-oxo-2′-deoxyguanosine, serum cholesterol oxidation products, and oxidation resistance of lipids in nondepleted men. Arteriosclerosis, Thrombosis, and Vascular Biology 2000; 20: 2087–2093
   PubMed Web of Science ®Google Scholar
• Morrow J.D., Hill K.E., Burk R.F., Nammour T.M., Badr K.F., Roberts L.J., II. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proceedings of National Academy of Sciences of USA 1990; 87: 9383–9387
   PubMed Web of Science ®Google Scholar
• Morrow J.D., Frei B., Longmire A.W., Gaziano J.M., Lynch S.M., Shyr Y., Strauss W.E., Oates J.A., Roberts L.J., II. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. New England Journal of Medicine 1995; 332: 1198–1203
   PubMed Web of Science ®Google Scholar
• Roberts L.J., II, Morrow J.D. Generation and actions of isoprostanes. Biochimica et Biophysica Acta 1997; 1345: 121–135
   PubMed Web of Science ®Google Scholar
• Morrow J.D., Roberts L.J., II. The isoprostanes: unique bioactive products of lipid peroxidation. Progress in Lipid Research 1997; 36: 1–21
   PubMed Web of Science ®Google Scholar
• Salonen J.T., Nyyssönen K., Salonen R., Lakka H.M., Kaikkonen J., Porkkala-Sarataho E., Voutilainen S., Lakka T.A., Rissanen T., Leskinen L., Tuomainen T.P., Valkonen V.P., Ristonmaa U., Poulsen H.E. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. Journal of Internal Medicine 2000; 248: 377–386
   PubMed Web of Science ®Google Scholar
• Nyyssönen K., Porkkala E., Salonen R., Korpela H., Salonen J.T. Increase in oxidation resistance of atherogenic serum lipoproteins following antioxidant supplementation: a randomized double-blind placebo-controlled clinical trial. European Journal of Clinical Nutrition 1994; 48: 633–642
   PubMed Web of Science ®Google Scholar
• Porkkala-Sarataho E., Nyyssönen K., Salonen J.T. Increased oxidation resistance of atherogenic plasma lipoproteins at high vitamin E levels in non-vitamin E supplemented men. Atherosclerosis 1996; 124: 83–94
   PubMed Web of Science ®Google Scholar
• Morrow J.D., Roberts L.J. Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as measure of oxidant stress. Methods in Enzymology 1999; 300: 3–12
   PubMed Web of Science ®Google Scholar
• Nyyssönen K., Pikkarainen S., Parviainen M.T., Heinonen K., Mononen I. Quantitative estimation of dehydroascorbic acid and ascorbic acid by high-performance liquid chromatography—application to human milk, plasma, and leucocytes. Journal of Liquid Chromatography 1988; 11: 1717–1728
   Web of Science ®Google Scholar
• Salonen R., Nyyssönen K., Porkkala E., Rummukainen J., Belder R., Park J.S., Salonen J.T. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92: 1758–1764
   PubMed Web of Science ®Google Scholar
• Salonen J.T., Nyyssönen K., Tuomainen T.P., Mäenpää P.H., Korpela H., Kaplan G.A., Lynch J., Helmrich S., Salonen R. Increased risk of non-insulin dependent diabetes mellitus at low plasma vitamin E concentrations: a four year follow up study in men. BMJ 1995; 311: 1124–1127
   PubMed Web of Science ®Google Scholar
• Valsta L.M. Food-based dietary guidelines for Finland—a staged approach. British Journal of Nutrition 1999; 81: S49–S55
   Google Scholar
• The National Institute of Public Health. The 1997 dietary survey of Finnish adults. Helsinki 1998; B8
   Google Scholar
• Gopaul N.K., Halliwell B., Anggard E.E. Measurement of plasma F2-isoprostanes as an index of lipid peroxidation does not appear to be confounded by diet. Free Radical Research 2000; 33: 115–127
   PubMed Web of Science ®Google Scholar
• Bachi A., Brambilla R., Fanelli R., Bianchi R., Zuccato E., Chiabrando C. Reduction of urinary 8-epi-prostaglandin F2 alpha during cyclo-oxygenase inhibition in rats but not in man. British Journal of Pharmacology 1997; 121: 1770–1774
   PubMedGoogle Scholar
• Lynch S.M., Morrow J.D., Roberts L.J., II, Frei B. Formation of non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vitro. Journal of Clinical Investigation 1994; 93: 998–1004
   PubMed Web of Science ®Google Scholar
• Moore K.P., Darley-Usmar V., Morrow J., Roberts L.J., II. Formation of F2-isoprostanes during oxidation of human low-density lipoprotein and plasma by peroxynitrite. Circulation Research 1995; 77: 335–341
   PubMed Web of Science ®Google Scholar
• Gniwotta C., Morrow J.D., Roberts L.J., II, Kuhn H. Prostaglandin F2-like compounds, F2-isoprostanes, are present in increased amounts in human atherosclerotic lesions. Arteriosclerosis, Thrombosis and Vascular Biology 1997; 17: 3236–3241
   PubMed Web of Science ®Google Scholar
• Pratico D., Iuliano L., Mauriello A., Spagnoli L., Lawson J.A., Rokach J., Maclouf J., Violi F., FitzGerald G.A. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. Journal of Clinical Investigation 1997; 100: 2028–2034
   PubMed Web of Science ®Google Scholar
• Wilson S.H., Best P.J., Lerman L.O., Holmes D.R., Jr, Richardson D.M., Lerman A. Enhanced coronary vasoconstriction to oxidative stress product, 8-epi-prostaglandin F2alpha, in experimental hypercholesterolemia. Cardiovascular Research 1999; 44: 601–607
   PubMed Web of Science ®Google Scholar
• Minuz P., Andrioli G., Degan M., Gaino S., Ortolani R., Tommasoli R., Zuliani V., Lechi A., Lechi C. The F2-isoprostane 8-epiprostaglandin F2alpha increases platelet adhesion and reduces the antiadhesive and antiaggregatory effects of NO. Arteriosclerosis, Thrombosis, and Vascular Biology 1998; 18: 1248–1256
   PubMed Web of Science ®Google Scholar
• Oguogho A., Mehrabi M., Sinzinger H. Increased plasma, serum and urinary 8-epi-prostaglandin F2alpha in heterozygous hypercholesterolemia. Wiener Klinische Wochenschrift 1999; 111: 113–118
   PubMedGoogle Scholar
• Oguogho A., Sinzinger H. Isoprostanes in atherosclerosis. Journal of Physiology and Pharmacology 2000; 51: 673–682
   PubMedGoogle Scholar
• Obata T., Tomaru K., Nagakura T., Izumi Y., Kawamoto T. Smoking and oxidant stress: assay of isoprostane in human urine by gas chromatographymass spectrometry. Journal of Chromatography. B, Biomedical Sciences and Applications 2000; 746: 11–15
   PubMedGoogle Scholar
• Pilz H., Oguogho A., Chehne F., Lupattelli G., Palumbo B., Sinzinger H. Quitting cigarette smoking results in a fast improvement of in vivo oxidation injury (determined via plasma, serum and urinary isoprostane). Thrombosis Research 2000; 99: 209–221
   PubMed Web of Science ®Google Scholar
• Pratico D., Iuliano L., Basili S., Ferro D., Camastra C., Cordova C., FitzGerald G.A., Violi F. Enhanced lipid peroxidation in hepatic cirrhosis. Journal of Investigative Medicine 1998; 46: 51–57
   PubMed Web of Science ®Google Scholar
• Wood L.G., FitzGerald D.A., Gibson P.G., Cooper D.M., Garg M.L. Lipid peroxidation as determined by plasma isoprostanes is related to disease severity in mild asthma. Lipids 2000; 35: 967–974
   PubMed Web of Science ®Google Scholar
• Reilly M.P., Delanty N., Roy L., Rokach J., Callaghan P.O., Crean P., Lawson J.A., FitzGerald G.A. Increased formation of the isoprostanes IPF2alpha-I and 8-epi-prostaglandin F2alpha in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. Circulation 1997; 96: 3314–3320
   PubMed Web of Science ®Google Scholar
• Salonen J.T. Markers of oxidative damage and antioxidant protection: assessment of LDL oxidation. Free Radical Research 2000; 33: S41–S46
   Google Scholar
• Pratico D., Tangirala R.K., Rader D.J., Rokach J., FitzGerald G.A. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nature Medicine 1998; 4: 1189–1192
   PubMed Web of Science ®Google Scholar
• Laight D.W., Desai K.M., Gopaul N.K., Anggard E.E., Carrier M.J. F2-isoprostane evidence of oxidant stress in the insulin resistant, obese Zucker rat: effects of vitamin E. European Journal of Pharmacology 1999; 377: 89–92
   PubMed Web of Science ®Google Scholar
• Davi G., Alessandrini P., Mezzetti A., Minotti G., Bucciarelli T., Costantini F., Cipollone F., Bon G.B., Ciabattoni G., Patrono C. In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology 1997; 17: 3230–3235
   PubMed Web of Science ®Google Scholar
• Meagher E.A., Barry O.P., Lawson J.A., Rokach J., FitzGerald G.A. Effects of vitamin E on lipid peroxidation in healthy persons. JAMA 2001; 285: 1178–1182
   PubMed Web of Science ®Google Scholar
• Packer J.E., Slater T.F., Wilson R.L. Direct observation of a free radical interaction between vitamin E and vitamin C. Nature 1979; 278: 737–738
   PubMed Web of Science ®Google Scholar
• Wilkinson I.B., Megson I.L., MacCallum H., Sogo N., Cockcroft J.R., Webb D.J. Oral vitamin C reduces arterial stiffness and platelet aggregation in humans. Journal of Cardiovascular Pharmacology 1999; 34: 690–693
   PubMedGoogle Scholar
• May J.M., Qu Z.C., Morrow J.D. Interaction of ascorbate and alpha-tocopherol in resealed human erythrocyte ghosts. Transmembrane electron transfer and protection from lipid peroxidation. Journal of Biological Chemistry 1996; 271: 10577–10582
   PubMed Web of Science ®Google Scholar
• Neutzil J., Thomas S.R., Stocker R. Requirement for promotion, or inhibition by alpha-tocopherol of radical-induced initiation of plasma lipoprotein lipid peroxidation. Free Radical Biology and Medicine 1997; 22: 57–71
   PubMedGoogle Scholar
• Blot, W.J., Li, J-Y., Taylor, P.R., Guo, W., Dawsey, S., Wang, G.Q., et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. Journal of the National Cancer Institute 1993; 85: 1483–1492
   PubMed Web of Science ®Google Scholar
• Stadtman E.R. Ascorbic acid and oxidative inactivation of proteins. American Journal of Clinical Nutrition 1991; 54: 1125–1128
   Web of Science ®Google Scholar
• Thomas S.R., Neuzil J., Stocker R. Cosupplementation with coenzyme Q prevents the prooxidant effect of α-tocopherol and increases the resistance of LDL to transition metal-dependent oxidation initiation. Arteriosclerosis, Thrombosis, and Vascular Biology 1996; 16: 687–696
   PubMed Web of Science ®Google Scholar
• The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. New England Journal of Medicine 1994; 330: 1029–1035
   PubMed Web of Science ®Google Scholar